Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 27, 2023 20:31 ET | Source: Scynexis

SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance

JERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® (ibrexafungerp tablets) to the consumer level in the US...
August 28, 2023 08:00 ET | Source: Scynexis

SCYNEXIS to Participate in September Investor Conferences

JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
August 14, 2023 16:30 ET | Source: Scynexis

SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

SCYNEXIS reported the closing of an exclusive license agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets). SCYNEXIS received an upfront payment of $90 million upon deal close.SCYNEXIS announced...
July 20, 2023 09:58 ET | Source: Scynexis

SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China

JERSEY CITY, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
June 21, 2023 07:00 ET | Source: Scynexis

SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK

JERSEY CITY, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
June 15, 2023 16:10 ET | Source: Scynexis

SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference

JERSEY CITY, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
May 12, 2023 08:00 ET | Source: Scynexis

SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)

SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of up to $503 million and tiered royalties.GSK obtains the exclusive rights to ibrexafungerp;...
May 11, 2023 07:00 ET | Source: Scynexis

SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update

SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront...
April 13, 2023 08:30 ET | Source: Scynexis

SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark

JERSEY CITY, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
March 31, 2023 08:30 ET | Source: Scynexis

SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

SCYNEXIS announced it has signed an exclusive agreement with GSK to commercialize and further develop BREXAFEMME® (ibrexafungerp tablets) for all indications. GSK will make an upfront payment to...